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Abstract
Urinary tract infections (UTIs) are some of the most common infections afecting humans worldwide. Occurrence of atypical, 
lactose non-fermenting, biochemically “inactive” strains of E. coli in clinical material has been described in the literature, 
which may cause a signiicant diagnostic challenge. The present retrospective microbiological study was carried out using 
isolates and data collected between January 1, 2013, and December 31, 2017, at the Institute of Clinical Microbiology. 
n = 24,285 positive urine samples were noted during the study period, out of which, samples positive for either lac + and lac- 
E. coli were included in the analysis. E. coli represented n = 7075 (55.8% ± 4.6%) of outpatient and n = 4916 (42.4% ± 3.6%) 
of inpatient isolates. n = 401 (3.3%; 80.2 ± 14.6/year) lac- E. coli isolates were identiied from urinary tract infections. The 
ratio of lac- E. coli isolates was signiicantly higher in outpatient samples (262 vs. 139). Resistance levels of lac- isolates for 
antibiotics commonly used for treating UTIs were signiicantly higher for both inpatient and outpatient isolates: norloxacin, 
ciproloxacin, fosfomycin and nitrofurantoin. It is essential to pay attention to the presence of lac- strains, and their omis-
sion from clinical material during diagnostic procedures may have signiicant consequences for epidemiological studies and 
therapy.
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Introduction
Urinary tract infections (UTIs) are some of the most com-
mon infections afecting humans worldwide; based on their 
prevalence, they are the third most common (following 
respiratory tract infections and gastrointestinal infections) 
infectious pathologies (Flores-Mireles et al. 2015; Behzadi 
and Behzadi 2016). Women have a 50% lifetime risk of 
developing UTIs at least once and 5% risk of having UTIs 
more than 5 times in their lifetime; for men, this risk is 
considerably lower (around 1–5%, especially for men aged 
50 years or older), which may be attributed to the anatomi-
cal diferences of the genitourinary tract among the two 
sexes (Stefaniuk et al. 2016; Magyar et al. 2017). UTIs are 
an important factor of morbidity for patients visiting out-
patient clinics, as well as hospitalized patients (especially 
ones undergoing urinary catheterization). In the latter group, 
these infections may represent 25–50% of communicable 
diseases overall (Maharjan et al. 2018). For this reason, 
UTIs should be considered an important inancial burden 
for patients (due to the symptoms and decreased quality 
of life), national economies (due to lost working days) and 
healthcare institutions (due to additional costs of pharmaco-
therapy, hospitalization and invasive procedures) (Foxman 
2003). The therapy of UTIs is also signiicantly hindered 
by the emergence of multidrug-resistant (MDR) bacterial 
strains, forcing clinicians to utilize drugs that are more 
expensive, are only available to be used intravenously, or 
that have pronounced toxicity in the patients (Milovanovic 
et al. 2019). The increasing resistance levels are especially 
 * Márió Gajdács 
 mariopharma92@gmail.com
1 Department of Pharmacodynamics and Biopharmacy, 
Faculty of Pharmacy, University of Szeged, Eötvös Utca 6., 
Szeged 6720, Hungary
2 Institute of Clinical Microbiology, Faculty of Medicine, 
University of Szeged, Semmelweis utca 6., Szeged 6725, 
Hungary
3 Department of Medical Microbiology and Immunobiology, 



























































































Journal : Large 42977 Article No : 16 Pages : 8 MS Code : 16 Dispatch : 4-6-2020
 Biologia Futura
1 3
worrisome in drugs primarily used to treat UTIs, namely 
trimethoprim/sulfamethoxazole, fosfomycin, nitrofurantoin 
and the luoroquinolones (Gajdács et al. 2019a; Jancel and 
Dudas 2002; Kaskatepe et al. 2017).
Members of the Enterobacterales order (previously: the 
Enterobacteriaceae family (Adelou et al. 2016)) are the 
most frequently associated with UTIs (including E. coli and 
Klebsiella, Citrobacter, Enterobacter, Serratia, Proteus, 
Morganella and Providencia species) (Park et al. 2017; 
Critchley et al. 2019); however, the pathogenic potential of 
Gram-positive cocci (Enterococcus spp., Staphylococcus 
aureus, S. saprophyticus), non-fermenting Gram-negative 
bacteria (e.g., Pseudomonas aeruginosa) (Gajdács et al. 
2019b) and various yeasts (e.g., Candida species) should 
also be taken into consideration (Behzadi et  al. 2015; 
Gajdács et al. 2019c). Nevertheless, the most common bac-
terial pathogen in UTIs is E. coli (namely uropathogenic 
E. coli or UPEC, recognized as a separate microbiological 
entity in the 1970s), corresponding to 70–95% of infections, 
based on various literature reports (Gajdács et al. 2019d; 
Behzadi 2019; Hozzari et al. 2020). E. coli is a commensal 
microorganism abundantly found in the gastrointestinal tract 
(producing Vitamin K for the host and having a protective 
role against other pathogens); however, if these bacteria 
breach into other anatomical regions, they act as opportun-
istic pathogens, owing to the plethora of virulence factors 
they possess (Gajdács et al. 2019d; Behzadi 2019; Hozzari 
et al. 2020; Jahandeh et al. 2015). E. coli is considered a 
biochemically active microorganism, while the hallmarks of 
biochemical identiication include the ability to ferment lac-
tose (lac +) and the decomposing of tryptophan into indole 
(Toledo and Trabulsi 1983). However, the occurrence of 
atypical, lactose non-fermenting (due to deiciency in the 
levels of lactose permease, encoded by lacY gene), often 
non-motile, biochemically “inactive” strains of E. coli in 
clinical material has been described in the literature, pre-
dominantly in the context of diarrheal (shigellosis-like) ill-
nesses (Nicoletti et al. 1988; Rychert and Stephenson 1986; 
Bajpai et al. 2016). These non-fermenting atypical variants 
(lac-) may cause a signiicant diagnostic challenge; in addi-
tion, the few reports available on the prevalence of these 
isolates have highlighted the potential of these strains to 
harbor various virulence- and antibiotic-resistance deter-
minants, clinically diferentiating them from lac + strains 
(Chang et al. 2014). Recently, an Australian study by Platell 
et al. highlighted that the lac- O75 clonal group of E. coli 
(a serotype that has been frequently associated with caus-
ing bacteremia and UTIs) had extensive levels of luoroqui-
nolone resistance (Platell et al. 2012).
There are very few comparative studies available on the 
epidemiological features and resistance levels of lac + and 
lac- strains of E. coli in clinical samples. Therefore, in the 
present study, our aim was to investigate the prevalence of 
non-lactose (lac-) fermenting E. coli in the context of urine 
specimens over a long surveillance period, to see whether 
diferential trends could be observed in the demographic 
characteristics of the afected patients and the antibiotic sus-
ceptibility of these isolates.
Materials and methods
Study design, data collection
The present retrospective microbiological study was carried 
out using data collected from the period between the January 
1, 2013, and December 31, 2017 (a 5-year time frame) at 
the Institute of Clinical Microbiology (University of Sze-
ged), which is the diagnostic microbiology laboratory of 
the Albert Szent-Györgyi Clinical Center, a primary- and 
tertiary-care teaching hospital in the Southern Great Plain 
of Hungary. Electronic search in the records of the MedBak-
ter laboratory information system (LIS) for urine samples 
positive for lac + and lac- E. coli (including identiication 
methods, biochemical test results, susceptibility testing 
results) was conducted by the authors (M.G., Á.M. and A.L.) 
(Gajdács et al. 2019d).
Samples with clinically signiicant colony counts for E. 
coli (> 105 CFU/mL; however, this was subject to interpre-
tation by the senior clinical microbiologists, based on the 
information provided on the clinical request forms for the 
microbiological analysis and international guidelines) that 
were positive for the nitrite and leukocyte-esterase tests were 
included in the data analysis (Gajdács et al. 2019a, d). Only 
the irst isolate per patient was included in the study; how-
ever, isolates with diferent antibiotic-susceptibility patterns 
from the same patient were considered as diferent individ-
ual isolates. To evaluate the demographic characteristics of 
these infections, patient data were also collected, which was 
limited to sex, age at the sample submission and inpatient/
outpatient status.
Identiication of isolates
Ten microliters of each un-centrifuged urine sample was 
cultured on eosine methylene blue (EMB; Bio-Rad, Berke-
ley, CA, USA) and UriSelect chromogenic agar plates (Bio-
Rad, Berkeley, CA, USA) with a calibrated loop, according 
to the manufacturer’s instructions and incubated at 37 °C 
for 24–48 h, aerobically. If relevant urinary pathogens (i.e., 
all isolates that were presumed to be Gram-negative bacte-
ria) presented in signiicant colony count, the plates were 
passed on for further processing. Identiication was primar-
ily based on colony color and morphology, in addition to 
the biochemical reaction-based VITEK 2 Compact ID/AST 
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the results of which were recorded (Gajdács et al. 2019a, 
d). For the veriication of discrepant identiication results, 
matrix-assisted laser desorption/ionization time-of-light 
mass spectrometry (MALDI-TOF MS by the Microflex 
MALDI Biotyper; Bruker Daltonics, Bremen, Germany) 
was utilized. The sample preparation methodology and the 
technical details for mass spectrometry measurements were 
described elsewhere (Takach et al. 1997). The MALDI Bio-
typer RTC 3.1 software (Bruker Daltonics) and the MALDI 
Biotyper Library 3.1 were used for spectrum analysis. Dif-
ferentiation of lac + and lac- E. coli strains was carried out 
based on the abovementioned tests.
Antibiotic susceptibility testing
Antimicrobial susceptibility testing was performed using the 
Kirby–Bauer disk difusion method (Lioilchem, Abruzzo, 
Italy) on Mueller–Hinton agar (MHA) plates, based on the 
methodological standards of EUCAST (EUCAST Clini-
cal breakpoints-breakpoints and Accessed 18 Mar 2020). 
In addition, for the veriication of discrepant results, the 
VITEK 2 Compact ID/AST (bioMérieux, Marcy-l’Étoile, 
France) automated system was also used (Gajdács et al. 
2019a, d). The following antibiotics were tested (with disk 
potencies in brackets): ampicillin (10 µg), amoxicillin/cla-
vulanic acid (10/10 µg), piperacillin (30 µg), cefotaxime 
(5 µg), ceftriaxone (30 µg), ceftazidime (10 µg), imipenem 
(10 µg), meropenem (10 µg), norloxacin (10 µg), ciproloxa-
cin (5 µg), gentamicin (10 µg), tobramycin (10 µg), amikacin 
(30 µg), tigecycline (15 µg), fosfomycin (200 µg with 50 µg 
glucose-6-phosphate), nitrofurantoin (100 µg), trimetho-
prim/sulfamethoxazole (1.25/23.75 µg).
The interpretation of the results was based on the oicial 
EUCAST breakpoints at the time of isolation (v.8.0-v.9.0). 
Phenotypic detection and conirmation of extended-spectrum 
β-lactamase (ESBL) production were carried out using the 
ESBL Disk Test Set (Lioilchem, Abruzzo, Italy) (Gajdács 
et al. 2019a, d). S. aureus ATCC 29213, E. faecalis ATCC 
29212, P. mirabilis ATCC 35659, E. coli ATCC 25922, K. 
pneumoniae ATCC 700603 and P. aeruginosa ATCC 27853 
were used as quality control strains. During data analysis, 
intermediately susceptible results were grouped with and 
reported as resistant.
Statistical analyses
Descriptive statistical analysis (including means or medians 
with ranges and percentages to characterize data) was per-
formed using Microsoft Excel 2013 (Redmond, WA, USA, 
Microsoft Corp.). Statistical analyses were performed with 
SPSS software version 24 (IBM SPSS Statistics for Win-
dows 24.0, Armonk, NY, USA, IBM Corp.), using the Chi-
square test or Student’s t test. The normality of variables was 
tested using Shapiro–Wilk tests. p values < 0.05 were con-
sidered statistically signiicant. Randomization of lac + E. 
coli sample was carried out using the RANDOM function 
in Microsoft Excel 2013 (Suresh 2011).
Results
Epidemiology, demographic characteristics
During the respective 5-year study period, n = 24,285 uri-
nary samples were received in the Institute of Clinical 
Microbiology that turned out to be positive for a signiicant 
urinary pathogen; out of these samples, n = 12,690 (52.3%) 
originated from outpatient clinics, while n = 11,595 (47.7%) 
was sent by inpatient departments (p > 0.05). The majority 
of samples were midstream urine (n = 18,107; 74.6%), fol-
lowed by catheter-specimen urine (n = 5299; 21.8%), while 
irst-stream urine (n = 859; 3.5%) and bladder tap (n = 20; 
0.1%) represented a minor fraction of urine samples.
Among the positive samples, E. coli represented 
n = 7075 (55.8% ± 4.6%) of outpatient isolates and n = 4916 
(42.4% ± 3.6%) of inpatient isolates, respectively; the highest 
percentages of E. coli among all urinary isolates were seen 
in 2015, while the lowest percentages were seen in 2017. 
Based on the phenotypic evaluation and the biochemical 
reactions by the VITEK 2 automated system, overall n = 401 
(3.3%; 80.2 ± 14.6/year) lac- E. coli isolates were identiied 
from urinary tract infections between 2013 and 2017. The 
ratio of lac- E. coli isolates was signiicantly higher in out-
patient samples (n = 262; 3.7%), than in inpatient samples 
(n = 139; 2.8%) (p = 0.021).
Due to the pronounced diferences (401 vs. 11,991) in 
the isolation rate of lac + and lac- E. coli, during statistical 
analyses (for demographic and susceptibility data), a ran-
dom sample of lac + E. coli was created and used, with a 
similar sample size of lac- isolates. Randomization was per-
formed n = 10 times (including n = 40 inpatient and n = 40 
outpatient isolates randomly, per each study year for a total 
of n = 400 lac + E. coli) to assess whether these individual 
random samples presented with statistically signiicant dif-
ferences. Based on the results of the preliminary statistical 
analysis, no relevant diferences were found; thus, during 
the comparisons between lac + and lac- E. coli isolates, a 
random lac + sample (n = 400, 200–200 from inpatient and 
outpatient samples, respectively) was utilized.
The demographic characteristics associated with the lac- 
and lac + samples are presented in Table 1. Overall, 73.8% 
(n = 295) of lac- samples and 70.8% (n = 284) lac + origi-
nated from female patients (p > 0.05). The median age of 
patients of the lac- groups did not show relevant diferences 
































































































































The number and ratio of resistant lac- and lac + E. coli iso-
lates (both from the inpatient and outpatient samples) are 
shown in Table 2. The highest levels of resistance were 
shown to norloxacin, ampicillin, ciproloxacin and trimetho-
prim/sulfamethoxazole in all sample groups, while lowest 
levels of resistance were shown against amikacin (< 5%), 
tigecycline (< 1%), imipenem and meropenem (0%). Over-
all, signiicant diferences were observed between the resist-
ance levels of the inpatient and outpatient sample groups for 
most of the β-lactam antibiotics (amoxicillin/clavulanic acid 
(5.6% vs. 10.9%; p = 0.039), cefotaxime (9.6% vs. 29.2%; 
p = 0.011), ceftriaxone (9.3% vs. 28.3%; p = 0.015), ceftazi-
dime (9.3% vs. 27.7%; p = 0.016)) and gentamicin (6.5% vs. 
15.1%; p = 0.02). The prevalence of ESBL-positive isolates 
was also higher in the inpatient isolates (9.3% vs. 27.7%; 
p = 0.016).
In contrast, such differences were not observed for 
β-lactams or any aminoglycosides if the groups were com-
pared based on their lac- and lac + status. On the other 
hand, resistance levels of lac- isolates for antibiotics com-
monly used for treating UTIs were signiicantly higher for 
both inpatient and outpatient isolates: norloxacin (outpa-
tients: 58.0% vs. 44.0%; p = 0.033, inpatients: 69.2% vs. 
51.0%; p = 0.024), ciproloxacin (outpatients: 29.0% vs. 
19.5%; p = 0.046, inpatients: 37.4% vs. 25.5%; p = 0.037), 
fosfomycin (outpatients: 10.3% vs. 6.0%; p = 0.037, inpa-
tients: 18.7% vs. 8.0%; p = 0.022) and nitrofurantoin (out-
patients: 4.6% vs. 2.0%; p = 0.049, inpatients: 6.5% vs. 
2.5%; p = 0.046) (Table 2). No signiicant correlation was 
found between lactose positivity and ESBL prevalence 
(p > 0.05).
Table 1  Demographic characteristics associated with lac- and lac + E. coli isolates (2013–2017)
Lac- isolates lac + isolates
Outpatient samples Inpatient samples Outpatient samples Inpatient samples
Number of isolates n = 262 n = 139 n = 200 n = 200
Median age (years) 54 73 52 72
Age range (years) 0.5–97 0.3–91 0.3–94 0.4–96
% of female patients afected 70.6% (n = 185) 71.2% (n = 99) 76.0% (n = 152) 71.5% (n = 143)
Table 2  Antibiotic susceptibilities associated with lac- and lac + E. coli isolates (2013–2017)
lac- isolates lac + isolates
Outpatient samples Inpatient samples Outpatient samples Inpatient samples
Number of isolates n = 262 n = 139 n = 200 n = 200
Ampicillin 45.0% (n = 118) 51.1% (n = 71) 48.0% (n = 96) 50.5% (n = 101)
Amoxicillin/clavulanic acid 5.3% (n = 14) 10.8% (n = 15) 6.0% (n = 12) 11.0% (n = 22)
Piperacillin 6.9% (n = 18) 12.2% (n = 17) 8.5% (n = 17) 11.0% (n = 22)
Cefotaxime 8.8% (n = 23) 28.1% (n = 39) 10.5% (n = 21) 30.0% (n = 60)
Ceftriaxone 8.4% (n = 22) 26.6% (n = 37) 10.5% (n = 21) 29.5% (n = 59)
Ceftazidime 7.6% (n = 20) 26.6% (n = 37) 10.5% (n = 21) 28.5% (n = 57)
Imipenem 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0)
Meropenem 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0)
Norloxacin 58.0% (n = 152) 69.2% (n = 96) 44.0% (n = 88) 51.0% (n = 102)
Ciproloxacin 29.0% (n = 76) 37.4% (n = 52) 19.5% (n = 39) 25.5% (n = 51)
Gentamicin 6.1% (n = 16) 15.1% (n = 21) 7.0% (n = 14) 15.0% (n = 30)
Tobramycin 4.6% (n = 12) 8.6% (n = 12) 5.5% (n = 11) 8.5% (n = 17)
Amikacin 2.7% (n = 7) 3.5% (n = 5) 3.5% (n = 7) 4.5% (n = 9)
Tigecycline 0% (n = 0) 0.7% (n = 1) 0% (n = 0) 0.5% (n = 1)
Fosfomycin 10.3% (n = 27) 18.7% (n = 26) 6.0% (n = 12) 8.0% (n = 14)
Nitrofurantoin 4.6% (n = 12) 6.5% (n = 9) 2.0% (n = 4) 2.5% (n = 5)
































































E. coli is the most common cause of urinary tract infec-
tions in both community and healthcare settings; the epi-
demiological signiicance of E. coli UTIs has also been 
highlighted in the context of our study. The pathogenic 
role of E. coli was noted by several reports from inter-
national organizations: The World Health Organization 
has designated it to the priority-pathogen list (to facilitate 
the development of novel antimicrobial agents), while the 
Infectious Disease Society of America (IDSA) included 
it among the “ESKAPE” pathogens, pertaining to bacte-
ria causing the highest levels of morbidity and mortal-
ity worldwide (Rajendran et al. 2019; Gajdács 2019). E. 
coli is a microorganism that may cause life-threatening 
infections: The various subtypes of entero-virulent E. coli 
(EEC) strains are principal causes of diarrheal illnesses, 
both in the Western world and in developing countries 
(Ochoa and Contreras 2011). Among the extra-intestinal 
pathogenic E. coli (ExPEC) strains, UPEC isolates are 
the most common; nevertheless, sepsis-associated E. 
coli (SEPEC) and neonatal meningitis-associated E. coli 
(NMEC) strains have the potential to cause invasive, often 
lethal infections (Manges et al. 2019; Köhler and Dobrindt 
2011). Lactose non-fermenting E. coli strains have simi-
larly been implicated in the pathogenesis of diarrhea, UTIs 
and invasive infections (Thompson et al. 1990; Barcaite 
et al. 2012).
In our study, the primary isolation of the bacteria from 
urine samples was carried out on eosine methylene blue 
and UriSelect chromogenic agar plates; although these 
culture media may have a role in the phenotypic misi-
dentiication of lac + and lac- strains in our local context, 
there are no data (from the literature or from our personal 
experiences) suggesting that the isolation frequency dif-
fers during the use of these culture media. Thus, all E. coli 
isolates (in fact, all Gram-negative bacteria isolated from 
urine samples) were included in the identiication process 
for the VITEK automated system which has been exten-
sively characterized as a reliable method for identiication 
and susceptibility testing of Gram-negative bacteria. Any 
discrepancies were clariied during the use of the MALDI-
TOF MS system; as this method employs a protein-based 
identiication system (irrespective of the lac + or lac- sta-
tus of the strains) (Takach et al. 1997), there was very 
limited chance of misidentiication or misrepresentation 
in our results.
From a clinical perspective, it is important to attain the 
knowledge about the most frequent etiological agents of 
UTIs and their susceptibility-levels to predict the clinical 
course of an infection and to select for adequate empiric 
antibiotic therapy (Abbo and Hooton 2014). However, it 
may be diicult to interpret the results of several authors 
as in most cases, biochemical characteristics (as diferen-
tiating factors, e.g., lac- and lac + status) are not reported 
for the respective strains; therefore, it is not possible to 
ascertain which bacterial population is being referred to, 
e.g., in a sample of E. coli (Bajpai et al. 2016). To the best 
of our knowledge, this is the irst study in Hungary, regard-
ing the prevalence and resistance levels of lactose non-
fermenting E. coli in urinary tract infections or otherwise. 
Among the main indings of our study, 3.3% (correspond-
ing to n = 401 isolates) of E. coli was shown to be lac- over 
a 5-year surveillance period, which we compared to a strat-
iied random sample of n = 400 lac + E. coli. Although the 
lac- strains represented a minor fraction of representative 
isolates, our study highlights that these bacteria may be 
misidentiied or misrepresented in epidemiological stud-
ies, where only tube-based, presumptive biochemical tests 
are utilized (Barcaite et al. 2012). Resistance levels against 
β-lactams were signiicantly higher in isolates originating 
from inpatients; this inding has also been demonstrated in 
our previous studies (Gajdács et al. 2019a, d).
In the following, a brief summary is presented regarding 
the available literature on the diferential aspects of lac- and 
lac + E. coli clinical isolates. Among the irst reports on the 
subject was the publication of Thompson et al., reporting 
a prevalence of 4.0% for lac- E. coli; in this study, the iso-
lates were originating from stool samples and most of the 
lac- E. coli isolates were Verotoxin producers (Thompson 
et al. 1990). Versalovic et al. estimated that around 5.0% of 
all E. coli clinical isolates (irrespective of the sample type) 
should be a lactose non-fermenter (Versalovic et al. 2011). 
This ratio has been proven to be correct by the study of 
Barcaite et al. from Lithuania, during which the study group 
screened pregnant women and neonates for Group B Strep-
tococcus and E. coli colonization (Barcaite et al. 2012). In 
consecutive studies from India (starting in 1995), Bhat et al. 
showed that 12.4% of urinary E. coli isolates are lactose 
non-fermenters (Bhat and Bhat 1995), while in studies with 
similar settings, Raksha et al. (in 2003) (Raksha et al. 2003), 
Radha et al. (in 2010) (Radha and Jeya 2010) and Bajpai 
et al. (in 2016) (Bajpai et al. 2016) detected lac- E. coli in 
9.0%, 6.3% and 3.6% of urine samples, respectively. Kacz-
marek et al. characterized n = 58 lac- and lac + E. coli bac-
teria isolated from pregnant women and neonates in Poland, 
using phenotypic and genotypic methods; in their report, 
lac- isolates showed higher levels of resistance to ticarcillin 
and ticarcillin/clavulanic acid, while no diference was seen 
in the number of genes carried for virulence factors (Kac-
zmarek et al. 2017; Kaczmarek et al. 2011). Yaratha et al. 
compared the epidemiological and clinical characteristics 
of n = 150 lac- and lac + E. coli clinical isolates from urine 
samples in a New York tertiary-care hospital: In this report, 
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respective infections. However, they have noted that lac- iso-
lates showed signiicantly higher levels of resistance to third 
generation cephalosporins and cefepime, while no such dif-
ference was seen for other urinary antibiotics (Yaratha et al. 
2017). Hossain et al. characterized lac- isolates isolated from 
stool samples in Bangladesh: In this study, 16.0% of E. coli 
were lac-, and non-fermenters showed signiicantly higher 
levels of resistance to luoroquinolones and trimethoprim/
sulfamethoxazole (Hossain 2012). The highest prevalence 
of non-fermenters was seen in a report from the Republic 
of Korea by Chang et al.: 19.7% were lac- and the 075 sero-
type was the most prominent among tested strains; however, 
they have found higher resistance in lac + E. coli against 
ciproloxacin (Chang et al. 2014). The pronounced difer-
ences among the reported isolation frequencies (~ 3–20%) 
may be attributable to several factors: (i) As most of these 
studies discussed mainly used common culture media for the 
primary isolation of these species from the clinical samples, 
diferential levels of isolation are presumably not due to the 
“loss at culture,” which is a common phenomenon, when 
considering fastidious microorganisms; (ii) the workup of 
diferent sample types (i.e., urine, stool, high vaginal swabs 
and so on) entails the use of diferent ancillary culture media 
and diferent incubation times (24–72 h), which may afect 
the expression of diferent enzymes, the sensitivity/speci-
icity of the media and therefore, the detection rate of lac- 
isolates; (iii) depending of the inancial situation of clinical 
microbiology laboratories, diferent identiication schemes 
may put into place: Some laboratories are only capable of 
using tube-based presumptive tests, others may use semi-
automated (e.g., API) or automated biochemical identiica-
tion (e.g., VITEK), and the most up-to-date institutions may 
utilize MALDI-TOF MS and PCR; all of these methods have 
diferent sensitivities and relevance in detecting lac- isolates; 
(iv) the interest and precision at the selection of colonies 
during diagnostic processes and the attitude toward the exact 
identiication and characterization of these UTI pathogens 
may also play a role; as in most cases, laboratories do not 
bother with the detailed characterization of the causative 
agents to this extent, because they do not consider this as 
a potential diagnostic inaccuracy; in addition, most clini-
cians are only concerned with susceptibility results to guide 
therapy.
In our study results, the median age of the affected 
patients in the inpatient and outpatient groups varied consid-
erably; however, this factor is probably unrelated to the lac-
tose-fermentation status of these E. coli strains. More prob-
ably, this corresponds to the common phenomenon seen in 
the demographic characteristics of outpatient and inpatient 
UTIs; most of the outpatient samples usually originate from 
younger patients with a better general health status and less 
exposure to antibiotics; on the other hand, inpatient sam-
ples originate from older, hospitalized patients. The latter 
patient group is commonly afected by underlying condi-
tions, and their lifetime antibiotic exposure is also consider-
ably higher. This also corresponds to the higher resistance 
levels observed in inpatient samples. This phenomenon has 
been described in a plethora of studies, both in Hungary and 
elsewhere. Multidrug resistance in UTIs is a signiicant clin-
ical problem (especially in the members of Enterobacterales, 
where the levels of ESBL- and carbapenemase-producing 
isolates are rapidly growing), which resulted in the “renais-
sance” in the utilization of older antibiotics, some of which 
have been speciically used for the treatment of UTIs. Fos-
fomycin, nitrofurantoin, mecillinam should all be considered 
as irst-line antibiotics for uncomplicated urinary infections, 
while methenamine—a urinary antiseptic—has also been 
re-discovered in the twenty-irst century (Ahmed et al. 2016; 
Doesschate et al. 2020). Fluoroquinolones have been exten-
sively used for the therapy of UTIs; however, due to recent 
development regarding their side-efect proile (the Food 
and Drug Administration has issued a “black box” warn-
ing on their use) and the growing levels of drug resistance, 
their use as irst-line agents in most clinical indications has 
been discouraged (Yarrington et al. 2019). Highlighting the 
signiicance of biochemical parameters, lac- isolates were 
signiicantly more prone to be resistant to luoroquinolone 
antibiotics and drugs that should be used in the irst line for 
uncomplicated UTIs.
Conclusions for future biology
Bacterial infections are still one of the most important 
factors of morbidity and mortality among communicable 
illnesses, and urinary tract infections are one of the most 
common infection types in human medicine. Gut bacteria, 
and among this group, E. coli is the most important uri-
nary pathogen in both uncomplicated urinary tract infec-
tions of outpatient and in hospitalized patients; therefore, 
the precise knowledge of the epidemiological characteris-
tics and susceptibility of these microorganisms is of utmost 
importance. The rapid emergence of antibiotic resistance in 
urinary pathogens is a global public health issue, afecting 
most Gram-negative bacteria. Most E. coli strains are bio-
chemically active; however, it is essential to pay attention to 
the presence of atypical, lac- strains: Their omission from 
the clinical material during diagnostic procedures may have 
signiicant consequences for epidemiological studies and 
therapy. Our study has presented the relevance of lac- strains 
of E. coli over a long surveillance period, to encourage other 
diagnostic laboratories to pay close attention to this variant 
of E. coli. Based on the limited amount of available ind-
ings in the literature, diferential workup of various clinical 
samples, the use of ancillary culture media, the interest and 
precision during selection of colonies during diagnostic pro-
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were identiied as possible explanations for the variable iso-
lation frequency of lac- strains.
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